{"paper_id":"1cf5a184-3368-47ed-8106-449caf8d3024","body_text":"Zusammenfassung\nHintergrund\nEndometriose ist eine der häufigsten gutartigen, jedoch chronischen Erkrankungen der Frau in der reproduktiven Lebensphase. Hauptsymptome sind chronische, i.d.R. zyklusabhängige Unterbauchschmerzen und Infertilität. Ätiologie und Pathogenese sind noch unzureichend geklärt, eine kurative Therapie existiert bisher nicht. Neben der operativen Entfernung ist die medikamentöse Behandlung die zweite wichtige Therapiesäule. Bei Kinderwunsch ergibt sich zudem oft die Indikation für eine assistierte Reproduktion.\nDiskussion\nVorrangiges Ziel der medikamentösen Therapie ist das Erreichen eines hypoöstrogenen Zustands. Hierfür kommen hormonelle Therapeutika, insbesondere orale Kontrazeptiva (OC), Gestagene und GnRH(„gonadotropin releasing hormone“)-Analoga infrage. Im Rahmen experimenteller Verfahren stehen Aromataseinhibitoren, GnRH-Antagonisten, selektive Östrogenrezeptormodulatoren (SERM) und selektive Progesteronrezeptormodulatoren (SPRM) zur Verfügung. Alternativ zur Hormontherapie können neben nichtsteroidalen antiinflammatorischen Medikamenten (NSAID) auch COX(Cyclooxygenase)-2-Inhibitoren, Angiogeneseinhibitoren und Immunmodulatoren eingesetzt werden. Alternative Ansätze, insbesondere bei ausgeprägter Schmerzsymptomatik, stellen zum einen die multimodale Schmerztherapie dar, sowie komplementäre Verfahren, z. B. Akupunktur, Physiotherapie und Phytotherapie.\nFazit\nEin evidenzbasierter Effekt dieser Therapien konnte bisher nicht durch randomisierte kontrollierte Studien eindeutig belegt werden. Der Beitrag fasst die systemischen Alternativen zur Hormontherapie zusammen.\nAbstract\nBackground\nEndometriosis is a one of the most common, benign but chronic diseases in women of reproductive age. The main symptoms are chronic and as a rule cycle-dependent pelvic pain and infertility. The etiology and pathogenesis of endometriosis are still unclear, a curative therapy is still lacking and the established options for therapy are mostly symptomatic. Other than surgical removal in this case laparoscopy is the gold standard, drug therapy plays an important role. In cases of infertility there is often an indication for assisted reproductive treatment.\nDiscussion\nThe main aim of drug therapy is to achieve a hypoestrogenic state; therefore, oral contraceptives, gestagens and gonadotropin-releasing hormone (GnRH) analogues are used. Experimental options include aromatase inhibitors, GnRH antagonists, selective estrogen receptor modulators (SERM) and selective progesterone receptor modulators (SPRM). Furthermore, nonsteroidal anti-inflammatory drugs (NSAIRs), cyclooxygenase (COX)-2 inhibitors, angiogenesis inhibitors and immunomodulators can also be used.\nConclusion\nEspecially for women with severe pelvic pain syndrome a multimodal pain therapy should be offered, for example, acupuncture, physiotherapy or phytotherapy are complementary treatment options, although not being evidence based. This study gives an overview of current non-invasive non-hormonal treatment options.\nSimilar content being viewed by others\nLiteratur\nAllen C, Hopewell S, Prentice A, Gregory D (2009) Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev:CD004753\nBecker CM, Sampson DA, Rupnick MA et al (2005) Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 84(suppl 2):1144–1155\nBedaiwy M, Casper R (2006) Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril 86:220–222\nBuelke-Sam J, Bryant HU, Francis PC (1998) The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod Toxicol 12(3):217–221\nCavaggioni G et al (2014) Are mood and anxiety disorders and alexithymia associated with endometriosis? A preliminary study. BioMed Res Int 5 (article ID 786830)\nCetinkaya N, Attar R, Yildirim G et al (2014) The effects of different doses of melatonin treatment on endometrial implants in an oophorectomized rat endometriosis model. Arch Gynecol Obstet\nChabbert-Buffet N, Pintiaux A, Bouchard P (2012) The imminent dawn of SPRMs in obstetrics and gynecology. Mol Cell Endocrinol 358(2):232–243\nDarling AM (2013) A prospective cohort study of Vitamins B, C, E, and multivitamin intake and endometriosis. J Endometr 5(1):17–26\nDonnez J, Smoes P, Gillerot S et al (1998) Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 13(6):1686–1690\nhttp://www.endometriose-liga.eu/symptomatische-behandlung. Zugegriffen: 20. September 2014\nFinas D, Hornung D, Diedrich K, Schultze-Mosgau A (2006) Cetrorelix in the treatment of female infertility and endometriosis. Expert Opin Pharmacother 7(15):2155–2168\nHan YF et al (2009) A survey of TCM treatment for endometriosis. J Tradit Chin Med 29(1):64–70\nHarris H (2013) Dairy-food, calcium, magnesium, and vitamin D intake and endometriosis: a prospective cohort study. Am J Epidemiol 177(5):420−430. doi:10.1093/aje/kws247\nHayes EC, Rock JA (2002) COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv 57(11):768–780\nHo HN, Wu MY, Yang YS (1997) Peritoneal cell immunity and endometriosis. Am J Reprod Immunol 38:400–412\nKawano Y, Nasu K, Li H et al (2011) Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target. Hum Reprod 26(9):2486–2498\nKocadal NÇ, Attar R, Yıldırım G et al (2013) Melatonin treatment results in regression of endometriotic lesions in an ooferectomized rat endometriosis model. J Turk Ger Gynecol Assoc 14(2):81–86\nLaschke MW, Menger MD (2012) Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update 18(6):682–702\nLin PY et al (2014) Bian zheng lun zhi as a complementary and alternative treatment for menstrual cramps in women with dysmenorrhea: a prospective clinical observation. Evid Based Complement Alternat Med 11 (article ID 460386)\nLiu X, Yuan L, Guo SW (2010) Valproic acid as a therapy for adenomyosis: a comparative case series. Reprod Sci 17(10):904–912\nMcLaren J (2000) Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 6(1):45–55\nNawathe A, Patwardhan S, Yates D et al (2008) Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG 115:818–822\nSharma I, Dhawan V, Saha SC, Dhaliwal LK (2011) In vitro effects of peroxisome proliferator-activated receptor-γ ligands on gene expression in lipopolysaccharide-induced endometrial and endometriotic stromal cells. Fertil Steril 95(2):829–831.e1–5\nStratton P, Sinaii N, Segars Jet al (2008) Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol 111(1):88–96\nSchindler AE (2008) Operative und medikamentöse Therapie der Endometriose/Adenomyose. J Gynakol Endokrinol 18:18–26\nVercellini P, Somigliana E, Viganò P et al (2009) Endometriosis: current therapies and new pharmacological developments. Drugs 69(6):649–675\nZito G, Luppi S, Giolo E et al (2014) Medical treatments for endometriosis-associated pelvic pain. BioMed Res Int 12 (article ID 191967)\nEinhaltung ethischer Richtlinien\nInteressenkonflikt. J. Braun, S.D. Schäfer und L. Kiesel geben an, dass kein Interessenkonflikt besteht.\nDieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nBraun, J., Schäfer, S. & Kiesel, L. Systemische Therapie der Endometriose: Alternativen zur Hormontherapie. Gynäkologe 48, 237–242 (2015). https://doi.org/10.1007/s00129-014-3421-1\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00129-014-3421-1","source_license":"CC0","license_restricted":false}